Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Zilovertamab Vedotin Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (52)
Zilovertamab Vedotin Follicular Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (52)
Zilovertamab Vedotin Mantle Cell Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (52)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Renal Pelvis Urothelial Carcinoma	Fred Hutchinson Cancer Center	P1/2	CCC (52)
immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative Solid Cancer	Daiichi Sankyo	P2/3	CCC (52)
rc48-adc Peritoneal Metastases	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P1/2	CCC (52)
T-Dxd Non-Small Cell Lung Carcinoma	Iambic Therapeutics, Inc	P1/2	CCC (52)
Trastuzumab Deruxtecan Gastroesophageal Junction Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CCC (52)
AEX4089DC1 Anal Cancer	MacroGenics	P2	CCC (51)
ARX 788 TNBC - Triple-Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Datopotamab Deruxtecan Metastatic Malignant Neoplasm In The Brain	Latin American Cooperative Oncology Group	P2	CCC (51)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Malignant Pancreatic Neoplasm	University of Kansas Medical Center	P2	CCC (51)
Gemtuzumab Ozogamicin Chronic Myelomonocytic Leukemia	M.D. Anderson Cancer Center	P2	CCC (51)
hlx43 Colorectal Cancer	Shanghai Henlius Biotech	P2	CCC (51)
hlx43 Pancreatic Ductal Adenocarcinoma	Shanghai Henlius Biotech	P2	CCC (51)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Urothelial Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (51)
immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative Metastatic Malignant Neoplasm	Daiichi Sankyo	P2	CCC (51)
Inotuzumab Ozogamicin Immunotherapy	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Loncastuximab Tesirine High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement	University of California, Davis	P2	CCC (51)
Loncastuximab Tesirine Richter Transformation	City of Hope Medical Center	P2	CCC (51)
rc48-adc Cholangiocarcinoma	SOLTI Breast Cancer Research Group	P2	CCC (51)
rc48-adc Colorectal Adenocarcinoma	SOLTI Breast Cancer Research Group	P2	CCC (51)
rc48-adc Colorectal Neoplasm	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (51)
rc48-adc Epithelial Ovarian Cancer	SOLTI Breast Cancer Research Group	P2	CCC (51)
rc48-adc Large B-cell Lymphoma	University Health Network, Toronto	P2	CCC (51)

Showing 551 to 575 of 1,027 assets

PreviousPage 23 of 42Next